Sinorda Biomedicine   Report issue

For profit Phase 2
Founded: Suzhou China (2010)

Organization Overview

First Clinical Trial
2018
NCT04293965
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Jiangsu Sinorda Biomedicine Co., Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

lansoprazole (prevacid) (1 trial)

linaprazan (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Esophagitis (Phase 2)

Esophagitis, Peptic (Phase 2)

Gastroesophageal Reflux (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2